Medtronic today announced the $200 million acquisition of the Netherlands' Sapiens Steering Brain Stimulation to bulk up its neuromodulation offerings.
Nilesh Gupta, managing director of India's Lupin, told Bloomberg that his company gave Wockhardt a financial sizing up recently before deciding it didn't represent a good M&A target.
Scientists from three Boston institutions have created CellNet, a computer algorithm to assist scientists in their efforts to engineer specialized cells.
India's drug business has taken a big financial hit in the last years as the FDA has stopped some of its top players from shipping drugs to the U.S. But experts still see big potential in the industry, saying it will grow faster than other Indian industries, particularly if players shed their conservative approach and get involved in the global M&A mix that their larger competitors are benefiting from.
The news that Roche struck a deal to buy InterMune for $8.3 billion reportedly came at the expense of Chugai's investors.
Ever since Valeant Pharmaceuticals swooped in for a takeover, Allergan executives and analysts have suggested a way out: Allergan could hustle up its own deal. Now, a Valeant lawsuit could close that exit, at least for now.
Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.
InterMune has already bet a big chunk of money on its idiopathic pulmonary fibrosis drug Esbriet (pirfenidone). Now, Roche is laying $8.3 billion on the table, too. The Swiss drugmaker agreed to pay $74 per share, in cash, for the biotech company, to add the lung treatment to its own respiratory stable.
Roche has won the behind-the-scenes auction for InterMune and its late-stage drug for idiopathic pulmonary fibrosis, announcing Sunday that it is buying up the U.S. biotech for $8.3 billion.
On Thursday, a judge ruled that an Allergan lawsuit against Valeant wouldn't delay a potential special meeting of Allergan shareholders, at which the Canadian pharma hoped to oust the Botox-maker's board and strike its takeover defenses. The news came not a moment too soon for Valeant, which now says it has successfully rounded up the support needed to call that meeting.